NCT07099677 Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk
| NCT ID | NCT07099677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abant Izzet Baysal University |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 186 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 186 participants in total. It began in 2025-08-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the short-term effects of three commonly prescribed antihypertensive drug classes (beta-blockers, ACE inhibitors, and calcium channel blockers) on postural balance and fall risk in adults with newly diagnosed primary hypertension. The main questions it aims to answer are: * Do different antihypertensive drugs affect objective balance performance and fall risk? * What are the effects of these medications on dizziness and fear of falling? Researchers will use a balance analysis system (Biodex Balance System) and self-reported scales (Dizziness Handicap Inventory and Falls Efficacy Scale) to assess outcomes. Participants will: * Be randomly assigned to one of three drug groups (metoprolol, ramipril, or amlodipine) * Be evaluated at baseline (prior to treatment), at 2 weeks, and at 4 weeks after starting treatment * Complete balance tests and questionnaires at each time point This study aims to provide clinical insight into how commonly used blood pressure medications may impact balance and fall risk in real-world settings.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 75 years * Newly diagnosed with primary hypertension * No prior use of antihypertensive medication * No history of neurological, vestibular, orthopedic, or psychiatric conditions affecting balance * Able to walk independently without assistive devices * Provided written informed consent to participate in the study Exclusion Criteria: * Secondary hypertension * Known diagnosis of vestibular disorders (e.g., BPPV, Ménière's disease) * Use of medications that may affect balance (e.g., sedatives, psychotropic drugs) * History of falls due to trauma unrelated to balance * Cognitive impairment preventing proper test participation * Inability to complete the assessments at follow-up timepoints (2nd and 4th week)
Contact & Investigator
Alp Ozel, PT, PhD
PRINCIPAL INVESTIGATOR
Abant Izzet Baysal University
Frequently Asked Questions
Who can join the NCT07099677 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07099677 currently recruiting?
Yes, NCT07099677 is actively recruiting participants. Contact the research team at alpozel@ibu.edu.tr for enrollment information.
Where is the NCT07099677 trial being conducted?
This trial is being conducted at Bolu, Turkey (Türkiye).
Who is sponsoring the NCT07099677 clinical trial?
NCT07099677 is sponsored by Abant Izzet Baysal University. The principal investigator is Alp Ozel, PT, PhD at Abant Izzet Baysal University. The trial plans to enroll 186 participants.